{"id":"W3088595788","doi":"10.1016/j.annonc.2020.08.2246","title":"LBA18 Overall survival (os) results from SOLAR-1, a phase III study of alpelisib (ALP) + fulvestrant (FUL) for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Novartis Pharmaceuticals Canada","keywords":"Medicine; Internal medicine; Hazard ratio; Fulvestrant; Population; Aromatase inhibitor; Progression-free survival; Oncology; Breast cancer; Cancer; Chemotherapy; Aromatase; Confidence interval; Estrogen receptor","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004023674,0.0006492005,0.002346535,0.0001729952,0.0001817939,0.00001274885,0.0004265599,0.0003403772,0.0004700128],"category_scores_gemma":[0.0005410875,0.0006041066,0.0003958102,0.0003969899,0.0004972441,0.0004865612,0.000148782,0.0005737379,0.000009442498],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000251352,"about_ca_system_score_gemma":0.0005451192,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003854657,"about_ca_topic_score_gemma":0.0007044554,"domain_scores_codex":[0.9952195,0.0004634118,0.001726329,0.001150377,0.0006241991,0.0008162027],"domain_scores_gemma":[0.9945413,0.001205764,0.001530797,0.0005149874,0.001679968,0.000527199],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.2415944,0.008808338,0.001330342,0.0002092308,0.004297984,0.00008973445,0.0386246,0.0001247447,0.5369629,0.0001743833,0.005200217,0.1625831],"study_design_scores_gemma":[0.3027666,0.1156038,0.1738234,0.0007077349,0.001264588,0.00004178815,0.0242936,0.0001952611,0.3626474,0.001175359,0.01537804,0.002102454],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9667387,0.0006272403,0.0005816248,0.01512276,0.0004072667,0.002996039,0.01306194,0.0000999253,0.0003645149],"genre_scores_gemma":[0.9932374,0.0005044424,0.002351737,0.00196105,0.0008646896,0.000311619,0.0005598092,0.0001157949,0.00009344345],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1743155,"threshold_uncertainty_score":0.999641,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07991196063309068,"score_gpt":0.3941266836991093,"score_spread":0.3142147230660186,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}